Skip to content
★ Sign in to follow
CL

CK Life Sciences Int'l., (Holdings) Inc. Stock: price and insider trades · Hong Kong

HK·Mcap HK$4.9BHealth Care

No insider purchase over the last 90 days. The latest, by Lee Yuen Lance Richard, was filed 12 Nov 2024.

CK Life Sciences Int'l., (Holdings) Inc.: what insiders have been doing

Every trade that managers of CK Life Sciences Int'l., (Holdings) Inc. disclose to HKEX is tracked on this page. The company sits in the Health Care sector and is based in Hong Kong, Hong Kong. It was founded in 2000. Nothing new has been filed by managers of CK Life Sciences Int'l., (Holdings) Inc. in twelve months, the latest record being from 24 March 2025.

Looking back to 2020, when coverage begins, insiders filed 4 purchases and 1 sale.

In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Source: insider filings from HKEX. Past trades are no guide to future returns.

Insider Decl.
6
Thresholds
n/a
Buy Volume
€210,694
4 ops. · all time
Sell Volume
€150,177
1 ops. · all time

Who traded when

BuySale
Kam Hing Lam1 sale

Since the insiders bought

  • Filed 12 Nov 2024 · 726 days ago · €116k
    +122.0%
    Entry HK$0.46 · Close at T+365 HK$1.01
  • Filed 11 Aug 2020 · 2280 days ago · €85k
    -12.9%
    Entry HK$0.93 · Close at T+365 HK$0.81

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 23,663 of 26,897 companies
23.8
score / 100
Value
24
Quality
23
FCF yld-1.2%
Earn yld-3.8%
EV/EBITDA23.3x
ROE-2.2%
Gross mgn29%
Net mgn-3.5%
Debt/EBITDA13.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$0.51
Analyst consensus
·
Income statement
RevenueHK$5.4B
Gross profitHK$1.6B29% margin
EBITDAHK$494.2M9% margin
Net income-HK$186.8M-1.2% margin
Valuation
P/Book1.2x
Beta0.45
Balance sheet & cash
Market capHK$4.9B
Total debtHK$6.6B
Free Cash Flow-HK$61M
Debt / Equity167%
Profitability & ownership
ROE-2.2%
ROA-0.1%
% insiders75.0%
% institutions0.4%
Last declaration on 24 March 2025
Declarations6 total
  • ▼
    DirectorExecutives
    1M HKD19HKEX
    2,300,000 shares@ HK$0.55100.0% of flowShareXHKGHKEX:DA20250324E00231
  • ▲
    DirectorExecutives
    969,363 HKD19HKEX
    2,130,000 shares@ HK$0.455192.7% of flowShareXHKGHKEX:DA20241112E00455
    Canonical exit: 9 Feb 2025 (T+90)
  • ▲
    DirectorExecutives
    24,570 HKD11HKEX
    54,000 shares@ HK$0.4552.3% of flowShareXHKGHKEX:DA20241112E00454
    Canonical exit: 4 Feb 2025 (T+90)
  • ▲
    DirectorExecutives
    52,780 HKD11HKEX
    116,000 shares@ HK$0.4555.0% of flowShareXHKGHKEX:DA20241112E00453
    Canonical exit: 3 Feb 2025 (T+90)
  • ●
    DirectorExecutives
    726,240 HKD16HKEX
    816,000 shares@ HK$0.8948.4% of flowShareXHKGHKEX:DA20210723E00283
  • ▲
    DirectorExecutives
    775,200 HKD16HKEX
    816,000 shares@ HK$0.9551.6% of flowShareXHKGHKEX:DA20200811E00190
    Canonical exit: 8 Nov 2020 (T+90)

6 of 6 declarations

About CK Life Sciences Int'l., (Holdings) Inc.

CK Life Sciences Int'l., (Holdings) Inc. is a company listed on the Hong Kong Stock Exchange, specializing in life sciences. It focuses on research and development of health and environmental-related products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations